Prebiotics are considered to have potential to reduce disturbances in the gut microbiota induced by antibiotics. Results in literature are, however, not consistent. The current in vitro study conducted in a fermentation screening platform allowed to unambiguously compare the impact of galacto-oligosaccharides (GOS) on adult gut microbiota composition and activity upon treatment with four antibiotics at two doses. The changes in relative abundance of bacteria upon antibiotic treatment and the growth of Bifidobacterium and Lactobacillus upon GOS addition were antibiotic and dose dependant. This conclusion explains discrepancies in literature and indicates that particular combinations of GOS antibiotic should be studied. The combination GOSAmoxicillin was especially of interest as, after decrease in Bifidobacterium levels, a recovery of mainly Bifidobacterium longum was observed and could be correlated with specific degradation patterns of GOS. Next to different degradation profiles of individual GOS, an accumulation of monosaccharides and intermediate organic acids was observed in antibiotic-treated microbiota as compared to nontreated microbiota. This showed that although GOS were utilized and beneficial bacteria could grow in 3 of 4 antibiotics tested, the metabolic activity of an antibiotic-treated microbiota was still disturbed as compared to the nontreated microbiota.
Introduction
Fermentation of nondigested compounds reaching the human colon requires the cooperation of different bacterial groups and results in the production of gases and short chain fatty acids (SCFAs) (Blaut & Clavel, 2007) . The complex microbiota and its metabolic activity are relatively stable in various stages of life for each individual, but can be disrupted by, for example, antibiotic treatments or modulated with prebiotic supplementations (Preidis & Versalovic, 2009) .
In Europe, the median consumption of antibiotic was 18.3 defined daily doses per 1000 inhabitants per day in 2010. The most commonly used antibiotics were penicillins followed by macrolides and tetracyclines (ECEC surveillance report, 2010) . These antimicrobial agents are used to treat specific bacterial infections, but can also kill or inhibit bacteria that are not primarily targeted, such as bifidobacteria and lactobacilli within the gut microbiota (Br€ otz-Oesterhelt & Brunner, 2008) . The extent of the impact of an antibiotic on the nontargeted microbial populations depends on its spectrum of action, mode of administration (oral vs. intravenous), dose and absorption rate (Sullivan, 2001) . The resulting disruption of the microbiota can be the basis for the occurrence of metabolic dysfunctions, leading to a decrease in beneficial SCFA levels and to an increase in unfermented oligosaccharides (Yap et al., 2008) . In 5-35% of the cases, it can also lead to antibiotic-associated diarrhoea (AAD), with the antibiotics amoxicillin and clindamycin having the highest incidence (McFarland, 2008 ).
Prebiotics are defined as 'selectively fermented ingredients that allow specific changes, both in the composition and in the activity of the gastrointestinal microbial communities that confer benefits upon host well-being and health' (Gibson et al., 2004) . Most known prebiotics are fructo-oligosaccharides and galacto-oligosaccharides (GOS). The use of prebiotics to prevent nonantibioticassociated gut diseases is promising (Gibson et al., 2005) . With respect to the prevention of AAD, only a few studies have been performed. The results are contradictory regarding the efficacy to limit the risk of AAD and the impact on the microbiota composition (Macfarlane et al., 2006; Preidis & Versalovic, 2009; Saulnier et al., 2009) . Main focus was on the number of Bifidobacterium, as these bacteria are expected to be stimulated by the prebiotic addition. The number of Bifidobacterium was reported to either increase (Lewis et al., 2005a) , decrease (Hopkins & Macfarlane, 2003) or remain stable (Lewis et al., 2005b) . Discrepancies regarding the effect of prebiotic addition on antibiotic-treated microbiota might be explained by the variability in parameters among the studies. Parameters, such as prebiotics, antibiotics, dosages and age of subjects, are known to have a high impact on the microbiota composition (Macfarlane & Macfarlane, 2009) . Using a fermentation screening platform, this study aims to unambiguously compare the potential beneficial impact of a commercially available prebiotic, GOS, on an adult microbiota treated with four antibiotics at two doses. The microbiota composition was investigated as well as the microbiota metabolic activity, specifically oligosaccharide degradation and organic acid production.
Materials and methods

Antibiotics
Amoxicillin (AMX) (≥ 90%), ciprofloxacin (CIP) [≥ 98% high-performance liquid chromatography (HPLC)], clindamycin hydrochloride (CLI) (impurities ≤ 2 mol/mol EtOH) and doxycycline (DOX) (≥ 98% TLC) were obtained from Sigma-Aldrich (St Louis, MO). These antibiotics belong to four of the most widely used classes of antibiotics used in Europe (ECEC surveillance report, 2010) and were selected based on their different modes of action (Table 1) .
Prebiotic
Purified GOS with < 3% (w/w dry matter) monomers and lactose (purified from the lactose-based prebiotic Vivinal â GOS, FrieslandCampina Domo, Borculo, the Netherlands) were used. Vivinal â GOS were purified because monosaccharides and lactose are digested and absorbed in the small intestine. For the purification, Vivinal â GOS were enzymatically treated with a lactase to hydrolyse the lactose into glucose and galactose, after which the monosaccharides were removed by nanofiltration. The degree of polymerization (DP) of the purified GOS ranged from 2 to 8.
Experimental set-up
In a fermentation screening platform (96 wells of 1.5 mL), selected type and dose of antibiotics (1 or 10 lg mL
À1
) and GOS (4.2 mg mL
) were simultaneously added to the standard ileal efflux medium (SIEM) and in vitro fermented (37°C; pH 5.8) using healthy adult faecal inoculum (0.1% v/v) under anaerobic conditions (Ladirat et al., 2013) . Selection of volunteers (n = 8) and methodology to obtain and store the faecal samples were performed as described previously (Ladirat et al., 2013) . Polymeric carbohydrates present in the SIEM were used as nonprebiotic substrate in the control (Ladirat et al., 2013) . Each fermentation was performed in triplicate. To investigate the microbiota metabolic activity, samples (70 lL) were collected six times during fermentation. The collection times were chosen based on a test experiment revealing the time range of GOS degradation. This range was between 8 and 24 h fermentation in the control, between 16 and 32 h and between 24 and 48 h in the fermentations using 1 and 10 lg mL À1 antibiotic, respectively (data not shown). The collected samples were then boiled (5 min) and stored at À20°C. To investigate the changes in the microbiota composition, additional samples (70 lL) were collected from the same well at 24, 32 and 48 h, as the fermentation rate may be slowed down by antibiotic addition and stored at À20°C. 
Microbiota composition analysis
The Intestinal (I)-chip, developed at TNO (Zeist, the Netherlands), was used to investigate the composition of the microbiota. This DNA-based microarray enabled the detection of more than 400 bacterial targets from the human large intestinal microbiota. Total faecal DNA from collected samples was isolated, amplified, purified and hybridized as described previously (Ladirat et al., 2013) . The hybridization took place on a microarray constructed and validated as described before (2011), using intestinal bacteria primers instead of oral primers. ImaGene 5.6 software (BioDiscovery, Marina del Rey, CA) was used to analyse the results. Genes above the detectable level having a signal intensity higher than 3 (> 10 5 bacteria) in more than 10 samples were used to describe the bacterial fingerprint.
Total bacteria and Bifidobacterium quantification using quantitative PCR Quantitative PCR (qPCR) was performed to investigate the variation in the total number of bacteria and Bifidobacterium during fermentation. Primers used to measure the total number of bacteria were the universal primers 16S-uni-II-R [10 pmol lL ] (GAC CAT GCA CCA CCT GTG AAC) and 16S-Bifspec (6FAM-CTG GGC TTG ACA TGT T) (Applied Biosystems, Bleiswijk, the Netherlands). The amplification was performed with 5 lL DNA sample and 25 lL q-PCR mixture (Ladirat et al., 2013) . Total microbial faecal DNA was diluted 1 : 10 to quantify the total number of bacteria and 1 : 100 to quantify the number of Bifidobacterium. The experiment was performed using the 7500 Fast Real-Time PCR system (Applied Biosystems) at settings previously described (Ladirat et al., 2013) .
DNA of the microbiota from the control and Bifidobacterium longum was used as quantitative standards for total bacteria and Bifidobacterium, respectively (5 ng lL
).
Statistical analysis
To evaluate whether two qPCR data sets were significantly different, a Student's t-test was performed. P-values were calculated assuming equal variance and two-tailed distribution. Correlations were considered significant at a P-value lower than 0.01.
GOS degradation pattern using highperformance anion exchange chromatography (HPAEC)
HPAEC was performed to quantify GOS degradation during the experiments. The samples collected were 10x diluted with Millipore water (0.42 mg mL
À1
) and analysed using an ICS 3000 HPLC system (Dionex, Sunnyvale, CA), equipped with a CarboPac PA-1 column (2 mm ID 9 250 mm; Dionex) in combination with a CarboPac PA guard column (2 mm ID 9 25 mm) and an ISC 3000 ED detector ( To describe the degradation of GOS over fermentation time, GOS were roughly subdivided based on the DP (Coulier et al., 2009) : dimers (DP < 3, incl. 3% monomers) eluting between 4.5 and 9.7 min, medium-sized DP (3 ≤ DP≤5) eluting between 9.7 and 13.0 min, and large DP (DP > 5) eluting between 13.0 and 18.0 min. The peak areas were measured to express the remaining oligosaccharides as an indication of the degradation rate. Degradation patterns were similar for the triplicate samples. Proportion of remaining oligosaccharides was quantified only in one set of samples.
SCFA and organic acid production using gas chromatography (GC) and HPLC A GC analysis (2006) was performed on a TRACE TM GC Ultra gas chromatograph system coupled with a FID detector (Interscience, Breda, the Netherlands) to quantify the SCFA (acetate, propionate and butyrate) produced during fermentation: 50 lL of diluted sample (0.42 mg mL À1 ) or standards (1-0.125 mg mL
) mixed with 50 lL of 0.15 M oxalic acid stood for 30 min before addition of 150 lL of water. Samples (1 lL) were injected to a CP-FFAP CB column (25 m 9 0.53 mm 9 1.00 lm) (Agilent Technologies, Santa Clara, CA). The temperature profile was as follows: start at 100°C, increase to 155°C at 5°C min À1 and hold at this temperature 1 min. GC data were integrated using the Xcalibur â software (Thermo Scientific, Breda, the Netherlands). The concentration of organic acids was expressed as lmol mg À1 of GOS.
HPLC was performed to quantify lactate and succinate on a Ultimate 3000 HPLC (Dionex) equipped with an RI-101 refractive index detector (Shodex, Kawasaki, Japan), an autosampler and an ion-exclusion Aminex HPX -87H column (7.8 9 300 mm) with a guard column (Bio-Rad, Hercules, CA). The mobile phase was 5 mM H 2 SO 4 and the flow rate was 0.6 mL min À1 at 65°C. Diluted samples (10 lL; 0.42 mg mL
) and standards (10 lL; 0.125-1 mg mL À1 ) were injected onto the column. SCFA production was quantified only in one set of samples.
Results
To determine the potential beneficial impact of GOS on antibiotic-treated microbiota composition and metabolic activity (substrate degradation and SCFA production), in vitro fermentations using adult faecal inoculum treated with four antibiotics (AMX, CIP, CLI, DOX) at two doses (low: 1 lg mL À1 or high: 10 lg mL
À1
) were performed in a fermentation screening platform.
Impact of GOS on the microbiota composition
Total bacteria and Bifidobacterium quantification
The total numbers of bacteria and Bifidobacterium in AntiBiotic-treated MicroBiota (AB-MB) and in antibiotictreated microbiota supplemented with GOS (AB/GOS-MB) as measured with qPCR are presented in Table 2 . Overall, the total number of bacteria remained stable upon GOS addition. The number of Bifidobacterium increased upon GOS addition depending on the antibiotic, dose and time. The increase was significant (P < 0.01) for CIP/GOS-MB (+ 1.6 log 10 ) and CLI/GOS-MB (+ 0.8 log 10 ) applied with a 10 lg mL À1 dose, although the number of Bifidobacterium was still below that of the nontreated microbiota (10 7.8 copies g À1 faeces AE 0.6). The number of Bifidobacterium upon GOS addition increased significantly (P < 0.01) and reached a level that was similar to GOS-MB (10 9.6 copies g À1 faeces) for CIP/GOS-MB (+ 2.4 log 10 ) and DOX/GOS-MB (+ 2.2 log 10 ) applied with a 1-lg mL À1 dose, and for AMX/GOS-MB applied with a both 1 and 10-lg mL À1 dose (+ 2.9 log 10 and + 3.5 log 10 , respectively). At low dose, the Bifidobacterium stimulation was quicker for CIP/GOS-MB and DOX/GOS-MB (24 h of fermentation) than for AMX/GOS-MB (32 h of fermentation). The Bifidobacterium growth for AMX/GOS-MB at both low and high dose is of high interest as the Bifidobacterium level was first decreased due to the AMX action.
Microbiota fingerprinting as measured with the I-chip
The impact of GOS on the overall microbiota composition, including specific Bifidobacterium species, was determined using the I-chip by comparing AB/GOS-MB and AB-MB (Fig. 1) . For AB/GOS-MB, the addition of GOS did not influence the abundances of Bacteroides, Clostridium and Enterobacteriaceae. For the latter two bacterial groups, the abundance remained low upon GOS addition, which is preferable as most pathogens belong to these two bacterial groups. In AB/GOS-MB, an impact of GOS addition could be observed on the Lactobacillus and Bifidobacterium population at each dose of antibiotic. The increase in Lactobacillus was dose dependant: at low dose (1 lg mL
À1
), an increase in Lactobacillus brevis was observed upon addition of GOS after 24 h of fermentation in most samples (excluding AMX/GOS-MB), while ), an increase in L. gasseri was observed in CIP/GOS-MB and DOX/GOS-MB. The increase in Bifidobacterium was in line with results measured by qPCR. The I-chip results also showed that different species were stimulated upon GOS addition depending on the antibiotic treatment. For GOS-MB, a broad range of Bifidobacterium species became more abundant, mainly B. longum, B. thermophilum and B. adolescentis. For AB/GOS-MB, specific Bifidobacterium species were stimulated depending on the antibiotic and the dose. Using a low dose of antibiotic, mainly B. longum became more abundant for AMX/GOS-MB, while mainly B. longum, B. animalis and B. thermophilum for CIP/GOS-MB and mainly B. thermophilum, B. ruminantium and B. adolescentis for DOX/GOS-MB became more abundant. Using a high dose of antibiotic, mainly B. longum and B. thermophilum became more abundant for AMX/GOS-MB. For CIP/GOS-MB, Bifidobacterium were stimulated but no preferential growth of specific species was detected. As the same inoculum was used for all fermentations, it is clearly shown that within the same ecosystem, the stimulation of specific bacteria upon GOS addition depends on the antibiotic used.
Metabolic activity of antibiotic-treated microbiota supplemented with GOS
Degradation of the substrate GOS
As growth of Bifidobacterium and Lactobacillus was observed upon GOS addition in some antibiotic-treated microbiota, the degradation and utilization of GOS were determined. The HPAEC elution patterns of GOS during fermentation using nontreated microbiota are shown in Fig. 2 . A complex pattern of peaks can be observed at t = 0. Few peaks were attributed to compounds present in the growth medium (M), and two peaks were attributed to glucose/galactose (G, Retention time (Rt) = 4.5 min) and lactose (L, Rt = 6.3 min). Other peaks represented oligosaccharides with different DPs and isomers present in the GOS mixture (Coulier et al., 2009) . Over fermentation time, the different oligosaccharides were degraded at different rates. To visualize the degradation of GOS in nontreated microbiota and 1 or 10 lg mL
À1
antibiotic-treated microbiota during fermentation, the proportion of remaining oligosaccharides (% of peak area) is presented in Fig. 3 for total GOS and for oligosaccharides with a DP < 3, 3 ≤ DP≤ 5 and DP > 5. In GOS-MB, about 20% of the total GOS were utilized in the first 8 h of fermentation and further utilization occurred gradually until 24 h of fermentation. For AB/GOS-MB, a lag time of utilization was observed as more than 80% of GOS were still present after 16 and 24 h of fermentation when the 1 and 10 lg mL À1 doses was used, respectively. The subsequent utilization of GOS differed per antibiotic and per dose. About 40% of the GOS remained in CLI/GOS-MB after 34 and 48 h of fermentation at low and high dose, respectively. On the contrary, the degradation was almost complete (< 10% remaining GOS) for CIP/GOS-MB, AMX/GOS-MB and DOX/GOS-MB. Once the degradation started, the 80% remaining GOS were degraded quicker in CIP/GOS-MB (6 h), as quick as in AMX/GOS-MB (12 h) and slower in DOX/GOS-MB (17 h) than in GOS-MB. Oligosaccharides of DP < 3 were in most cases quickly utilized in 1 lg mL À1 treated samples, indicating an easy utilization by the microbiota. For AMX/GOS-MB, however, oligosaccharides of DP < 3 accumulated at the beginning of the fermentation before being fully utilized within 34 h of fermentation. For 10 lg mL À1 treated samples, oligosaccharides of DP < 3 remained present at 48 h of fermentation in all cases, which is in contrast to the fermentation pattern of GOS without antibiotic treatment. Oligosaccharides of 3 ≤ DP≤ 5 decreased gradually in time for each dose of antibiotic. These oligosaccharides were present over time, probably due to a balance between further utilization and formation. Oligosaccharides of DP > 5 were degraded slowly in Fig. 2 . HPAEC elution patterns of GOS during in vitro fermentation using nontreated adult microbiota. The complex mixture of GOS was roughly subdivided based on the DP (6). M: peak from the SIEM medium, G: glucose, L: lactose.
DOX/GOS-MB and quickly in AMX/GOS-MB and CIP/ GOS-MB for both doses. Overall, it can be concluded that different degradation profiles were observed after a same fermentation time depending on the antibiotic and dose used.
Production of SCFA
The degradation of GOS resulted in the production of organic acids: acetate (A), propionate (P), butyrate (B), succinate (S) and lactate (L) (Fig. 4) . For GOS-MB, the total amount of organic acids was 14 lmol mg substrate À1 , with a ratio of A : P : B : S : L of 79 : 6 : 6 : 8 : 1. For 1 lg mL À1 antibiotic-treated samples, different concentrations of organic acids were observed per antibiotic used. For AMX/GOS-MB, a lower total amount of organic acids was observed (9 lmol mg substrate À1 ), mainly acetate and succinate (A : P : B : S : L = 44 : 7 : 5 : 44 : 0). For CIP/ GOS-MB and DOX/GOS-MB, the amount and relative abundance of organic acids were similar to that of GOS-MB. For CLI/GOS-MB, a rather low amount of organic acids was observed (5 lmol mg substrate À1 ), mainly acetate. For 10 lg mL À1 treated samples, an overall reduction in organic acids was observed (below 9 lmol mg substrate À1 after 48 h of fermentation). Furthermore, the relative abundance of organic acids is dramatically changed as it mostly consists of lactic acid and acetate, whereas neither propionate nor butyrate could be detected. 
Discussion
Using a fermentation screening platform, a straightforward comparison of the impact of GOS on the gut microbiota treated with four antibiotics at two doses was possible. The antibiotics belong to the most widely used classes of antibiotics used in Europe. The doses selected (1 and 10 lg mL
À1
) are in the range of MIC values of currently used antibiotics (EUCAST breakpoints). The changes in the microbiota composition upon antibiotic treatment (Fig. 1) were in line with previous results (Ladirat et al., 2013) , except for the increase in Bifidobacterium after 1 lg mL À1 DOX treatment. The impact of tetracycline treatment, such as DOX, on Bifidobacterium has been reported to be variable due to the presence or absence of a resistance gene depending on the species (Masco et al., 2006) . Overall, the changes resulted in changes of metabolic activity, even upon the use of a sublethal dose as 1 lg mL À1 (Willing et al., 2011) .
Antibiotic-treated microbiota changes upon GOS addition
In AB/GOS-MB, changes in the microbiota composition were mainly detected for the Bifidobacterium and Lactobacillus, which was expected as GOS are prebiotics known to stimulate specifically these bacteria (Gibson et al., 2004) . The growth of other bacteria which may utilize the partly degraded substrate present was below the detection level and codependence that exists amongst members of the microbiota (Belenguer et al., 2006; Willing et al., 2011) was not observed. The changes in levels of Bifidobacterium and Lactobacillus were concomitant with the degradation of GOS and were antibiotic dependant (Table 3) . Bifidobacterium levels did not increase in CLI/GOS-MB at both doses within 32 h of fermentation, which is in line with the observed low degradation of GOS (about 40% remaining). Hence, partial degradation of GOS is likely due to the activity of Lactobacillus that are known to grow on GOS, but to a lesser degree than Bifidobacterium (Macfarlane et al., 2008) . On the contrary, levels of Bifidobacterium increased upon GOS addition in CIP/GOS-MB and in DOX/GOS-MB at low dose (1 lg mL
À1
). The growth of these bacteria was facilitated as they were not affected by CIP and DOX (Table 2) and could utilize GOS (Fig. 3) . Furthermore, the competition for GOS intermediate degradation products was reduced, for example lower levels of Bacteroides in DOX/ GOS-MB (Sonnenburg et al., 2006) . At high dose, the degradation of GOS occurred in both DOX/GOS-MB and CIP/GOS-MB, likely due to Lactobacillus gasseri action that was highly abundant (Table 3) . Finally, levels of Bifidobacterium, specifically B. longum, increased upon GOS in AMX/GOS-MB at both doses. This outcome is of high interest as the levels in the controls were low due to AMX action. The recovery of B. longum, therefore, reveals a potential beneficial effect of GOS addition in AMX-disturbed microbiota.
Degradation of GOS in antibiotic-treated microbiota
An almost complete degradation of GOS was observed in three antibiotic-treated microbiota using a low dose. The rate of degradation of oligosaccharides with different DPs varied depending on the antibiotic used. This preferential degradation was linked to the specific growth of Bifidobacterium species (Table 3) . The degradation of oligosaccharides of DP > 5 was quick for both AMX/GOS-MB and CIP/GOS-MB and correlated with the stimulation of mainly B. longum. This species is known to produce a membrane-bound extracellular endogalactanase that liberates galacto-trisaccharides from b(1,4) galactooligosaccharides (van den Broek et al., 2008) . It is probably due to the endoactivity of this enzyme that the oligosaccharides of DP > 5 are readily degraded. On the contrary, for DOX/GOS-MB, a fast degradation of small DP followed by a subsequent degradation of larger DPs was observed, which is characteristic for B. adolescentis (van den Broek et al., 2008; Barboza et al., 2009 ) that was stimulated. The correlation between GOS degradation and recovery of specific Bifidobacterium for specific antibiotic used indicates that preference of certain oligosaccharides by the microbiota is important to be considered when aiming at the recovery of this microbiota after an antibiotic treatment. Investigating in more detail which specific structure of GOS is preferentially degraded upon a specific antibiotic treatment could, for instance, ease the choice for an adequate synbiotic to be added during the antibiotic treatment to limit risk for AAD (Orrhage et al., 2000) . Another option could be to adjust the oligosaccharides composition of a prebiotic mixture depending on the antibiotic treatment used to stimulate specific Bifidobacterium present in the host gut. Significant difference between GOS and no GOS addition (P < 0.01). DP, Degree of Polymerization.
Metabolic activity of the microbiota after antibiotic treatment
The metabolic functions of the microbiota include the degradation of the substrate and production of organic acids, which are most often SCFA (Guarner & Malagelada, 2003) . In nontreated microbiota, the degradation of GOS resulted in high amount of SCFA and a low amount of intermediate acids as described before (Hopkins & Macfarlane, 2003; Hernot et al., 2009) . At low dose, for CIP/GOS-MB and DOX/GOS-MB, the profile of organic acids was similar to that of GOS-MB, indicating that the metabolic activity of the microbiota might be as good as in nontreated microbiota. In strongly disrupted microbiota, for example, 10 lg mL À1 AB-MB or 1 lg mL À1 CLI/ GOS-MB, monosaccharides accumulated and a low total content of organic acids was observed, which is consistent with literature (Yap et al., 2008) . The presence of monosaccharides that would usually be quickly utilized by the microbiota might be a reason for pathogen colonization, for example Clostridium difficile, during antibiotic treatment. Furthermore, a downward shift in the ratio SCFA/ intermediate acids was also observed in our study upon antibiotic treatment (Table 3 ), indicating that the ability to convert intermediate acids to SCFA was reduced. The presence of lactate and acetate is in line with the degradation of GOS by Bifidobacterium and Lactobacillus (Fooks & Gibson, 2003) . However, the absence of propionate and butyrate indicates that key groups of bacteria, such as Bacteroides and butyrate-producing bacteria, are lacking. Accumulation of succinate in 1 lg mL À1 treated samples revealed that the activity of mainly Bacteroides was affected, while accumulation of lactate in 10 lg mL À1 treated samples suggests that the lactate-utilizing bacteria were also affected. The altered concentrations of SCFA and intermediate organic acids are unusual in the colon. The impact on the differences in metabolites produced might have consequences on colon health.
Conclusions
Using a fermentation screening platform, our results clearly revealed that the recovery of an antibiotic-treated microbiota upon GOS addition is antibiotic dependant and, thereby, explains previous discrepancy in literature. The combination of GOS-AMX appeared to be of high interest as a recovery of mainly B. longum was observed and could be correlated with specific degradation patterns of GOS. Furthermore, the study emphasized that despite the specific growth of beneficial bacteria and the concomitant degradation of GOS, the metabolic activity of the antibiotic-treated microbiota may still be disturbed as compared to the nontreated microbiota. Further in vivo research should focus on the impact of specific structure of GOS to prevent intestinal diseases and on the consequences of the altered concentrations of SCFA and intermediate organic acids on colon health.
